Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Phio Pharmaceuticals Corp. - Common Stock (NQ: PHIO )

1.350 +0.050 (+3.85%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 131,224
Open 1.310
Bid (Size) 1.250 (7)
Ask (Size) 1.360 (10)
Prev. Close 1.300
Today's Range 1.240 - 1.370
52wk Range 1.220 - 9.990
Shares Outstanding 1,055,219
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting
Marlborough, Massachusetts--(Newsfile Corp. - March 10, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics... 
Via Newsfile
Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study
Marlborough, Massachusetts--(Newsfile Corp. - March 5, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics... 
Via Newsfile
Exposures Product Safety

Performance

YTD
-28.95%
-28.95%
1 Month
-24.16%
-24.16%
3 Month
-50.00%
-50.00%
6 Month
-51.61%
-51.61%
1 Year
-84.69%
-84.69%

More News

Read More
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Via Newsfile
Exposures Lead
Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors
Via Newsfile
What's Going On With Phio Pharmaceuticals Stock Today?
Via Benzinga
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Via Newsfile
Exposures Lead
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Via Newsfile
Exposures Lead
Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Via Newsfile
Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Via Newsfile
Topics Regulatory Compliance
Exposures Legal Regulatory
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Via Newsfile
Topics Regulatory Compliance
Exposures Legal Regulatory
Dow Gains Over 200 Points; Signet Jewelers Shares Plunge
Via Benzinga
Topics Stocks
Exposures US Equities
We Asked Retail What's Next For Phio Pharma After Monday's Blistering Rally: Most See More Room To Run
Via Stocktwits
Crude Oil Down 1%; Firefly Neuroscience Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Nasdaq Jumps 150 Points; US Producer Prices Increase 0.2% In December
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Via Newsfile
Topics Regulatory Compliance
Exposures Legal Regulatory
Why KB Home Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Stocks to Watch in 2025: PHIO, LPTH, KAVL, Promising Innovations, Growth Opportunities, Etc. … more inside
Via AB Newswire
Topics Regulatory Compliance
Exposures Legal Regulatory
Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge
Via Benzinga
Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why
Via Benzinga
Phio Pharma Stock Quadruples On Positive Data From Cancer Treatment Trial: Retail’s Elated
Via Stocktwits
Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge
Via Benzinga
Exposures Fossil Fuels
US Stocks Mixed; Nasdaq Down Over 1%
Via Benzinga
Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762
Via Newsfile
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.